Viewing Study NCT00325442



Ignite Creation Date: 2024-05-05 @ 4:49 PM
Last Modification Date: 2024-10-26 @ 9:24 AM
Study NCT ID: NCT00325442
Status: COMPLETED
Last Update Posted: 2017-08-02
First Post: 2006-05-11

Brief Title: FREEDOM-C Oral Treprostinil in Combination With an Endothelin Receptor Antagonist ERA andor a Phosphodiesterase-5 PDE-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension PAH
Sponsor: United Therapeutics
Organization: United Therapeutics

Study Overview

Official Title: A 16-Week International Multicenter Double-Blind Randomized Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination With an Endothelin Receptor Antagonist andor a Phosphodiesterase-5 Inhibitor in Subjects With Pulmonary Arterial Hypertension
Status: COMPLETED
Status Verified Date: 2017-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study was an international multi-center randomized double-blind placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH ie endothelin receptor antagonist andor phosphodiesterase-5 inhibitor Study visits occurred at 4 week intervals for 16 weeks the key measure of efficacy was the 6-minute walk test Study procedures included routine blood tests medical history physical exams disease evaluation and exercise tests One optional substudy was also a part of FREEDOM-C at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 16

Patients who completed all assessments for 16-weeks were also eligible to enter an open-label extension phase study FREEDOM - EXT
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None